Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
First FDA approved treatment in 30+ years for more than 2 million…
First market launch of the adrenaline nasal spray, EURneffy, for treatment of adults and children in Germany
ALK (ALKB:DC / OMX: ALK B) today announced the first market launch…
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal…
